fbpx
Loading
  • Twitter
  • Linkedin
  • Facebook
  • Gplus
  • Mail
  • Rss
  • Login
    • Password Reset
  • Register
(852) 3008 1717
Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong Kong
  • Health
  • Digital Marketing
  • Medical Writing
  • Contact Us
    • Request Quote
  • Search
  • Menu
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share by Mail

Conference Support

MediPaper joined the 25th Annual Meeting of the Chinese Society of Anaesthesiology


Medical Writer: Stijn van den Borne, MSc
Updated: 11 September 2017

Our Experience

YOU MAY ALSO LIKE

ASPEN CSA 2017 Prof Xue Zhanggang on TIVA Enhanced Recovery by Optimized Anesthetics

TIVA: enhanced recovery by optimized anesthetics

https://medi-paper.com/wp-content/uploads/2017/11/ASPEN-CSA-2017-Prof-Xue-Zhanggang-on-TIVA-Enhanced-Recovery-by-Optimized-Anesthetics.jpeg 1000 1500 Stijn van den Borne, MSc /wp-content/uploads/2018/10/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations.png Stijn van den Borne, MSc2017-11-23 16:06:422018-09-26 11:37:43TIVA: enhanced recovery by optimized anesthetics
Aspen CSA2017 the status of ERAS in China CSA2017 on the use of ERAS and TIVA in China

CSA2017: Prof Huang Yuguang on the use of ERAS and TIVA in China

https://medi-paper.com/wp-content/uploads/2017/11/Aspen-CSA2017-the-status-of-ERAS-in-China-CSA2017-on-the-use-of-ERAS-and-TIVA-in-China-1030x687.jpg 687 1030 Stijn van den Borne, MSc /wp-content/uploads/2018/10/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations.png Stijn van den Borne, MSc2017-11-07 22:23:132018-09-26 11:38:14CSA2017: Prof Huang Yuguang on the use of ERAS and TIVA in China
Aspen CSA2017 the status of ERAS in China CSA2017 on the use of ERAS and TIVA in China

CSA2017: Prof Xiong Lize on the status of ERAS in China

https://medi-paper.com/wp-content/uploads/2017/11/Aspen-CSA2017-the-status-of-ERAS-in-China-CSA2017-on-the-use-of-ERAS-and-TIVA-in-China-1030x687.png 687 1030 Stijn van den Borne, MSc /wp-content/uploads/2018/10/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations.png Stijn van den Borne, MSc2017-11-07 20:54:572018-09-26 11:38:41CSA2017: Prof Xiong Lize on the status of ERAS in China
PreviousNext

Almost 10,000 doctors from China joining together to learn about the latest developments in anaesthesiology.

MediPaper joined the 25th Annual Meeting of the Chinese Society of Anaesthesiology (CSA), held from 7-10 September 2017 in Zhengzhou, Henan Province, PR China.

We would like to extend our gratitude to the inviting partner, the CSA, and doctors for making time to meet our medical writer.

The Annual Meeting of the CSA, the official anaesthetist chapter of the Chinese Medical Association, is the largest anaesthesiology meeting in China.

  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
  • CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology
PreviousNext
123456789

© Copyright 2017 - MediPaper - 25th Annual Meeting of the Chinese Society of Anaesthesiology - CSA2017 - 中华医学会第25 次全国麻醉学术年会

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share by Mail

You may also like

innovent biologics anti-pd1 sintilimab plus biosimilar bevacizumab receive ind status by china nmpa

Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

https://medi-paper.com/wp-content/uploads/2018/10/innovent-biologics-anti-pd1-sintilimab-plus-biosimilar-bevacizumab-receive-ind-status-by-china-nmpa-e1539612467836.jpg 1000 1500 News Feed /wp-content/uploads/2018/10/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations.png News Feed2018-10-15 22:26:302018-10-15 22:26:30Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA
IMpower133 first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

https://medi-paper.com/wp-content/uploads/2018/10/IMpower133-first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung-cancer-e1539272789598.png 1000 1500 News Feed /wp-content/uploads/2018/10/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations.png News Feed2018-10-11 23:48:162018-10-11 23:48:16IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

U.S. FDA approved immune-checkpoint inhibitors updated 08-Oct-2018

https://medi-paper.com/wp-content/uploads/2017/08/U.S.-FDA-approved-immunecheckpoint-inhibitors--e1528903094981.jpg 1194 1254 Stijn van den Borne, MSc /wp-content/uploads/2018/10/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations.png Stijn van den Borne, MSc2018-10-09 08:00:012018-10-09 09:28:42U.S. FDA approved immune-checkpoint inhibitors updated 08-Oct-2018
Pembrolizumab plus chemotherapy effective in squamous NSCLC

Pembrolizumab plus chemotherapy effective in squamous NSCLC

https://medi-paper.com/wp-content/uploads/2018/10/Pembrolizumab-plus-chemotherapy-effective-in-squamous-NSCLC.jpg 1000 1500 News Feed /wp-content/uploads/2018/10/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations.png News Feed2018-10-08 00:43:132018-10-15 07:51:10Pembrolizumab plus chemotherapy effective in squamous NSCLC
Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer

https://medi-paper.com/wp-content/uploads/2018/10/Ipilimumab-plus-nivolumab-for-persistent-or-recurrent-ovarian-cancer.jpg 1000 1500 News Feed /wp-content/uploads/2018/10/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations.png News Feed2018-10-07 00:13:112018-10-07 00:21:30Ipilimumab plus nivolumab for persistent or recurrent ovarian cancer
Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

https://medi-paper.com/wp-content/uploads/2018/10/Brigatinib-prolongs-PFS-compared-to-crizotinib-in-ALK-Positive-NSCLC.jpg 1000 1500 News Feed /wp-content/uploads/2018/10/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations.png News Feed2018-10-05 17:27:422018-10-05 17:32:41Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC
CAR-T axicabtagene ciloleucel granted Orphan Drug Designation for B-Cell Lymphoma by the Japan MHLW

CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

https://medi-paper.com/wp-content/uploads/2018/10/CAR-T-axicabtagene-ciloleucel-granted-Orphan-Drug-Designation-for-B-Cell-Lymphoma-by-the-Japan-MHLW.jpg 1000 1500 News Feed /wp-content/uploads/2018/10/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations.png News Feed2018-10-05 15:24:252018-10-05 15:26:26CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)

https://medi-paper.com/wp-content/uploads/2018/10/FDA-Logo-2018-MediPR-Medi-Paper-MediPaper-Medical-Communications-Ltd.-.png 1000 1495 News Feed /wp-content/uploads/2018/10/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations.png News Feed2018-10-03 12:53:562018-10-03 15:00:37PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)
JAVELIN Lung 200 avelumab vs docetaxel in patients with pretreated advanced non-small cell lung cancer NSCLC

JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

https://medi-paper.com/wp-content/uploads/2018/10/JAVELIN-Lung-200-avelumab-vs-docetaxel-in-patients-with-pretreated-advanced-non-small-cell-lung-cancer-NSCLC.jpg 1000 1500 News Feed /wp-content/uploads/2018/10/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-medical-public-relations.png News Feed2018-10-02 01:01:252018-10-02 17:08:39JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC
PreviousNext
1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

You must be logged in to post a comment.

© Copyright 2017 - MediPaper - CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology

Therapeutic Areas

Get access to restricted content via WeChat

MediPaper Medical Communications Ltd Healthcare Writers Medical Writers Medical Writer Agency Hong Kong Medical Writing Services Solutions Quote 醫學寫作 香港 醫學作家香港 Wechat

Newsletter

 MediPR | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | Medical Communications Health Blog | Medical Writer Jobs | MediNews.asia | Anaesthesiology.asia
© 2016-2018 MediPaper Medical Communications Ltd | Medical Writer Hong Kong | 醫學寫作 | 醫學作家香港 | Privacy Policy | Terms of Service | Cookie Policy
  • Twitter
  • Linkedin
  • Facebook
  • Gplus
  • Mail
  • Rss
Latest global trends of health measure and impact on survival rate Latest global trends of health measure and impact on survival rate Nivolumab Renal Cell Cancer Symposium Highlight Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy
Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings

Cookies and Privacy on medi-paper.com

Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds: